{"id":"https://openalex.org/W4416634870","doi":"https://doi.org/10.1183/13993003.congress-2025.pa2474","title":"APG808, an anti-IL-4R\u03b1 monoclonal antibody, demonstrates safety, extended half-life, and sustained inhibition of type 2 inflammatory biomarkers","display_name":"APG808, an anti-IL-4R\u03b1 monoclonal antibody, demonstrates safety, extended half-life, and sustained inhibition of type 2 inflammatory biomarkers","publication_year":2025,"publication_date":"2025-09-27","ids":{"openalex":"https://openalex.org/W4416634870","doi":"https://doi.org/10.1183/13993003.congress-2025.pa2474"},"language":"en","primary_location":{"id":"doi:10.1183/13993003.congress-2025.pa2474","doi":"https://doi.org/10.1183/13993003.congress-2025.pa2474","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2025.pa2474","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Airway pharmacology and treatment","raw_type":"proceedings-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5016828717","display_name":"Amol P. Kamboj","orcid":"https://orcid.org/0000-0003-3611-7326","observed_orcids":["https://orcid.org/0000-0003-3611-7326"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amol Kamboj","raw_affiliation_strings":["1Apogee Therapeutics, Waltham, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Apogee Therapeutics, Waltham, MA, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103934431","display_name":"Erica Winter","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Erica Winter","raw_affiliation_strings":["1Apogee Therapeutics, Waltham, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Apogee Therapeutics, Waltham, MA, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Lauren Wood","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lauren Wood","raw_affiliation_strings":["1Apogee Therapeutics, Waltham, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Apogee Therapeutics, Waltham, MA, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Cecilia Hale","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Cecilia Hale","raw_affiliation_strings":["1Apogee Therapeutics, Waltham, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Apogee Therapeutics, Waltham, MA, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034350503","display_name":"Sai P. Thankamony","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sai Thankamony","raw_affiliation_strings":["1Apogee Therapeutics, Waltham, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Apogee Therapeutics, Waltham, MA, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112472191","display_name":"Carl L. Dambkowski","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carl Dambkowski","raw_affiliation_strings":["1Apogee Therapeutics, Waltham, MA, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Apogee Therapeutics, Waltham, MA, United States","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108329364","display_name":"Xiu Qin Lim","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiu Qin Lim","raw_affiliation_strings":["2CMAX Clinical Research, Adelaide, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2CMAX Clinical Research, Adelaide, Australia","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"PA2474","last_page":"PA2474"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.6942999958992004,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.6942999958992004,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10051","display_name":"Asthma and respiratory diseases","score":0.16279999911785126,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11503","display_name":"Cytokine Signaling Pathways and Interactions","score":0.013899999670684338,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/il-4-receptor-alpha","display_name":"IL-4 receptor alpha","score":0.7549999952316284},{"id":"https://openalex.org/keywords/il-13-signaling","display_name":"IL-13 signaling","score":0.8320000171661377},{"id":"https://openalex.org/keywords/il-4-signaling","display_name":"IL-4 signaling","score":0.9430000185966492},{"id":"https://openalex.org/keywords/type-2-inflammation","display_name":"type 2 inflammation","score":0.8640000224113464},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9459999799728394},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9570000171661377},{"id":"https://openalex.org/keywords/extended-half-life","display_name":"extended half-life","score":0.6980000138282776},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.5580000281333923},{"id":"https://openalex.org/keywords/dosing-interval","display_name":"dosing interval","score":0.6480000019073486}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8531000018119812},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.8159000277519226},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7269999980926514},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6207000017166138},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6191999912261963},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5906999707221985},{"id":"https://openalex.org/C61943457","wikidata":"https://www.wikidata.org/wiki/Q6046661","display_name":"Interim analysis","level":3,"score":0.5418999791145325},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.4999000132083893},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.477400004863739},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.4683000147342682},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3824000060558319},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3734000027179718},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.349700003862381},{"id":"https://openalex.org/C3018359032","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Safety profile","level":3,"score":0.34299999475479126},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.33320000767707825},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.29829999804496765},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.2971000075340271},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.29600000381469727},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.2865999937057495},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.2797999978065491},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.2750999927520752},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.27480000257492065},{"id":"https://openalex.org/C57992300","wikidata":"https://www.wikidata.org/wiki/Q2066956","display_name":"Potency","level":3,"score":0.2712000012397766},{"id":"https://openalex.org/C1621761","wikidata":"https://www.wikidata.org/wiki/Q7997549","display_name":"Whole blood","level":2,"score":0.2694999873638153},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.26429998874664307},{"id":"https://openalex.org/C79410662","wikidata":"https://www.wikidata.org/wiki/Q1251001","display_name":"Dose\u2013response relationship","level":2,"score":0.2612000107765198},{"id":"https://openalex.org/C163864487","wikidata":"https://www.wikidata.org/wiki/Q6901461","display_name":"Monoclonal","level":4,"score":0.2556999921798706},{"id":"https://openalex.org/C2776957806","wikidata":"https://www.wikidata.org/wiki/Q4895105","display_name":"Interim","level":2,"score":0.2500999867916107}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1183/13993003.congress-2025.pa2474","doi":"https://doi.org/10.1183/13993003.congress-2025.pa2474","is_oa":false,"landing_page_url":"https://doi.org/10.1183/13993003.congress-2025.pa2474","pdf_url":null,"source":{"id":"https://openalex.org/S4210207896","display_name":"European Respiratory Journal","issn_l":"0903-1936","issn":["0903-1936","1399-3003"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310317833","host_organization_name":"European Respiratory Society","host_organization_lineage":["https://openalex.org/P4310317833"],"host_organization_lineage_names":["European Respiratory Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Airway pharmacology and treatment","raw_type":"proceedings-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4415925180","https://openalex.org/W4417538140","https://openalex.org/W4401435979","https://openalex.org/W4400825273","https://openalex.org/W4403751877","https://openalex.org/W4396530736","https://openalex.org/W2170919145","https://openalex.org/W2808194525","https://openalex.org/W1959530901","https://openalex.org/W2889246099"],"abstract_inverted_index":{"Introduction:":[0],"APG808":[1,32,71,106,135,157,186],"is":[2],"an":[3,140],"optimized,":[4],"high-affinity,":[5],"half-life":[6,142],"extended,":[7],"fully":[8],"human":[9],"anti-IL-4R\u03b1":[10,118,209],"IgG1":[11],"monoclonal":[12],"antibody":[13],"that":[14,102,125,198],"inhibits":[15],"both":[16],"IL-13-":[17],"and":[18,28,81,86,110,128,193,213,227],"IL-4-mediated":[19],"signaling.":[20],"Aim:":[21],"To":[22],"evaluate":[23],"the":[24,79,113],"safety,":[25],"pharmacokinetics":[26],"(PK),":[27],"pharmacodynamics":[29],"(PD)":[30],"of":[31,65,70,97,117,143,156,163,183],"in":[33,231],"healthy":[34,45],"adult":[35,46],"participants.":[36],"Methods:":[37],"This":[38],"first-in-human":[39],"phase":[40],"1":[41],"trial":[42],"enrolled":[43],"32":[44],"participants":[47,54],"into":[48],"four":[49],"single-ascending":[50],"dose":[51,182,191],"cohorts.":[52],"Eight":[53],"per":[55],"cohort":[56],"were":[57,76,88,103,107],"randomized":[58],"6:2":[59],"to":[60,67,105,132,159],"receive":[61],"single":[62,179],"subcutaneous":[63],"doses":[64,155],"up":[66],"1200":[68,180],"mg":[69,181],"or":[72],"placebo.":[73],"Safety":[74],"assessments":[75],"conducted":[77],"throughout":[78],"study,":[80],"blood":[82],"draws":[83],"for":[84,224],"PK":[85,196],"PD":[87],"obtained":[89],"at":[90,147,168,174],"multiple":[91],"timepoints.":[92],"Results:":[93],"Through":[94],"12":[95,169],"weeks":[96,170],"follow-up,":[98],"adverse":[99],"events":[100],"(AEs)":[101],"related":[104,131],"generally":[108],"mild":[109],"consistent":[111],"with":[112,139,206,233],"known":[114],"safety":[115],"profile":[116,197],"therapy.":[119,210],"There":[120],"was":[121,126,166,187],"one":[122],"serious":[123],"AE":[124],"transient":[127],"considered":[129],"not":[130],"study":[133],"drug.":[134],"exhibited":[136,194],"target-mediated":[137],"PK,":[138],"estimated":[141],"approximately":[144],"55":[145],"days":[146],"projected,":[148],"clinically":[149],"relevant,":[150],"steady-state":[151],"exposure":[152],"levels.":[153],"Single":[154],"led":[158],"rapid,":[160],"near-complete":[161],"inhibition":[162],"pSTAT6,":[164],"which":[165],"sustained":[167,214],"(longest":[171],"follow-up":[172],"available":[173],"interim":[175],"analysis)":[176],"after":[177],"a":[178,195,201],"APG808.":[184],"Conclusion:":[185],"well":[188],"tolerated":[189],"across":[190],"groups":[192],"may":[199,221],"enable":[200],"longer":[202],"dosing":[203,229],"interval":[204],"than":[205],"currently":[207],"approved":[208],"The":[211],"deep":[212],"effect":[215],"on":[216],"type":[217,234],"2":[218,235],"inflammatory":[219,236],"biomarkers":[220],"indicate":[222],"potential":[223],"improved":[225],"outcomes":[226],"reduced":[228],"frequency":[230],"patients":[232],"diseases.":[237]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2025-11-25T00:00:00"}